CREST: Samphire Guided Care Program on Wellbeing, Work Productivity, and Quality of Life

Inclusion Criteria

• Self-identified female, aged 18-65 years at the time of enrollment
• Basic English literacy
• Able and willing to provide informed consent electronically
• Residing in the United States
• Reporting mood or cognitive symptoms associated with menstruation, perimenopause, or menopause (must endorse a minimum of three of the following: irritability, emotional dysregulation, brain fog, fatigue, reduced concentration, sleep disruption, or low mood)
• Symptoms present for at least 3 months and sufficiently severe to interfere with daily functioning, work performance, quality of life, or interpersonal relationships
• Currently in full-time employment with medical benefits as part of compensation package
• Access to a smartphone with internet access compatible with the Samphire mobile application
• Able to safely operate the study device in the home environment
• Willing to complete baseline, mid-program, and end-of-program questionnaires and engage with the 12-week guided care program

Exclusion Criteria

• Pregnancy, breastfeeding, or actively planning pregnancy during the study period
• History of epilepsy or seizure disorder
• Severe or unstable neurological disease that, in the opinion of the study team, may increase risk or interfere with participation
• Implanted electronic or metal devices in the head, neck, or brain region contraindicated for tDCS use
• Active scalp lesions, open wounds, or dermatologic conditions at electrode sites that may interfere with safe device use
• Current diagnosis of schizophrenia, bipolar disorder, or other severe psychiatric condition that would make participation inappropriate, as determined by screening
• Active suicidal ideation, recent suicidal behavior, or clinically significant self-injurious behavior, as determined by participant self-report during screening
• Inability to provide informed consent or safely use the device in the home environment
• Current participation in another interventional neurotechnology or drug study